对感染新型冠状病毒肺炎的实体瘤患者的临床结局、实验室及影像学数据进行评估。
Evaluation of clinical outcomes, laboratory and imaging data of patients with solid tumor infected with COVID-19 infection.
作者信息
Sadeghi Somayeh, Peikar Mohammadsaleh, Sadeghi Erfan, Darakhshandeh Ali, Ghafel Safie, Aalinezhad Marzieh, Sadeghi Alireza, Sharifi Mehran, Nasri Elahe
机构信息
Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences Isfahan, Iran.
Acquired Immunodeficiency Research Center, Al-Zahra Hospital, Isfahan University of Medical Sciences Isfahan, Iran.
出版信息
Int J Biochem Mol Biol. 2022 Dec 15;13(6):77-86. eCollection 2022.
BACKGROUND
COVID-19 is associated with higher mortality rates in patients with cancer. In this study, we aimed to evaluate the clinical outcomes, and laboratory and imaging data of patients with solid tumor infected with COVID-19 infection.
METHODS
This is a cross-sectional retrospective study performed in 2020-2022 on 85 patients with a previous diagnosis of solid tumors infected with COVID-19. We included all patients with tumors of solid organs that were diagnosed with COVID-19 infection and required hospitalization those patients previously hospitalized for treatments and were infected with COVID-19 during hospitalization. Demographic data of patients were collected using a checklist. We collected data regarding clinical outcome (discharge, hospitalization or death), duration of hospitalization, requiring ICU admission, duration of hospitalization divided by received drugs and type of tumor and mean survival time. Furthermore, we collected laboratory data from all patients. The radiologic characteristics of patients were also extracted from their data.
RESULTS
Breast cancer was the most common solid tumor (34.9%), followed by lung cancer (19.3%). The mortality rate was 24.1% (20 patients). The highest mortality rate in this study was for metastatic intestinal cancer to the lung (100%, one patient), followed by metastatic prostatic cancer to lung (50%, three patients). The highest hospitalization duration was for patients with glioblastoma multiform (GBM) (30 days). The mean survival time among patients with mortality was 19.15±1.80 days. The mean CT severity score of all patients was 27.53±22.90. Patient's most common radiologic sign was air space consolidation (89.1%). The highest CT severity score was found in patients with stomach cancer (46.67±5.77).
CONCLUSION
The mortality rate in this study was 24.1%. Based on the results of our study and previous research, special care should be provided to patients with solid tumors during the COVID-19 pandemic and in infected cases.
背景
新冠病毒病（COVID-19）与癌症患者的较高死亡率相关。在本研究中，我们旨在评估感染COVID-19的实体瘤患者的临床结局、实验室及影像学数据。
方法
这是一项于2020年至2022年开展的横断面回顾性研究，纳入85例先前诊断为实体瘤且感染COVID-19的患者。我们纳入了所有被诊断为感染COVID-19且需要住院治疗的实体器官肿瘤患者，以及那些先前因治疗住院且在住院期间感染COVID-19的患者。使用清单收集患者的人口统计学数据。我们收集了有关临床结局（出院、住院或死亡）、住院时间、是否需要入住重症监护病房、住院时间除以所接受药物、肿瘤类型及平均生存时间的数据。此外，我们收集了所有患者的实验室数据。患者的放射学特征也从其数据中提取。
结果
乳腺癌是最常见的实体瘤（34.9%），其次是肺癌（19.3%）。死亡率为24.1%（20例患者）。本研究中死亡率最高的是肺转移性肠癌（100%，1例患者），其次是肺转移性前列腺癌（50%，3例患者）。住院时间最长的是多形性胶质母细胞瘤（GBM）患者（30天）。死亡患者的平均生存时间为19.15±1.80天。所有患者的平均CT严重程度评分为27.53±22.90。患者最常见的放射学征象是实变影（89.1%）。胃癌患者的CT严重程度评分最高（46.67±5.77）。
结论
本研究中的死亡率为24.1%。基于我们的研究结果及先前研究，在COVID-19大流行期间及感染病例中，应对实体瘤患者给予特别护理。
Zotero 插件